Charles Schwab
ALXO icon

Charles Schwab’s ALX Oncology ALXO Stock Holding History

Charles Schwab’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$499K Buy
+241,113
New +$432K ﹤0.01% 3232
2025
Q3 		– Sell
-133,433
Closed -$55.4K – 3461
2025
Q2 		$55.4K Sell
133,433
-77,618
-37% -$39.2K ﹤0.01% 3445
2025
Q1 		$131K Sell
211,051
-5,656
-3% -$6.79K ﹤0.01% 3300
2024
Q4 		$362K Sell
216,707
-8,595
-4% -$13.2K ﹤0.01% 3232
2024
Q3 		$410K Sell
225,302
-10,718
-5% -$39.8K ﹤0.01% 3213
2024
Q2 		$1.42M Buy
236,020
+26,261
+13% +$323K ﹤0.01% 2807
2024
Q1 		$2.34M Buy
209,759
+1,595
+0.8% +$22.4K ﹤0.01% 2545
2023
Q4 		$3.1M Buy
208,164
+67,430
+48% +$640K ﹤0.01% 2499
2023
Q3 		$676K Sell
140,734
-24,817
-15% -$135K ﹤0.01% 2934
2023
Q2 		$1.24M Buy
165,551
+15,079
+10% +$98.7K ﹤0.01% 2697
2023
Q1 		$680K Sell
150,472
-9,513
-6% -$72.1K ﹤0.01% 2853
2022
Q4 		$1.8M Buy
159,985
+8,483
+6% +$95.3K ﹤0.01% 2601
2022
Q3 		$1.45M Sell
151,502
-211
-0.1% -$2.46K ﹤0.01% 2680
2022
Q2 		$1.23M Buy
151,713
+18,234
+14% +$199K ﹤0.01% 2719
2022
Q1 		$2.26M Sell
133,479
-6,403
-5% -$109K ﹤0.01% 2606
2021
Q4 		$3.01M Buy
139,882
+1,176
+0.8% +$50.7K ﹤0.01% 2570
2021
Q3 		$10.2M Buy
138,706
+46,002
+50% +$3.07M ﹤0.01% 1995
2021
Q2 		$5.07M Buy
92,704
+1,734
+2% +$104K ﹤0.01% 2349
2021
Q1 		$6.71M Buy
90,970
+18,939
+26% +$1.49M ﹤0.01% 2156
2020
Q4 		$6.21M Buy
72,031
+14,107
+24% +$849K ﹤0.01% 2113
2020
Q3 		$2.19M Buy
+57,924
New +$2.28M ﹤0.01% 2464

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Charles Schwab's ALXO Position: Q2 2026 in Review

Charles Schwab opened a new position in ALX Oncology (ALXO) in Q2 2026: 241,113 shares worth $499K. The stake represents ﹤0.01% of the portfolio and ranks #3232 among its holdings. This is a return to the name: Charles Schwab previously reported a position in ALXO as recently as Q2 2025.

Charles Schwab first reported a position in ALXO in Q3 2020 and has held it in 21 quarters since. The position peaked at $10.2M in Q3 2021. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Charles Schwab held 241,113 shares of ALX Oncology worth $499K as of Q2 2026.
  • ALX Oncology was a new Charles Schwab position in Q2 2026.
  • ALX Oncology made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3232 holding.
  • Charles Schwab first reported a position in ALX Oncology in Q3 2020 and has held it in 21 quarters since.
  • Charles Schwab's ALX Oncology position peaked at $10.2M in Q3 2021.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.